Durable and Drastic Response to the Trastuzumab, Letrozole, Abemaciclib, and Goserelin Combination as First-Line Therapy in HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer: A Case Report
We believe that the combination of trastuzumab, hormone suppression, and abemaciclib is a practicable and effective treatment for HER2-positive and HR-positive metastatic BC in premenopausal patients who cannot tolerate the first-line chemotherapy.
Authors
- Siwanon Jirawatnotai (ORCID: https://orcid.org/0000-0002-8252-3782)
- Ployploen Phikulsod (ORCID: https://orcid.org/0000-0001-5389-1896)
- Harit Suwanrusme
- Suthida Suwanvecho
- Narongsak Kiatikajornthada
Institutions
- Siriraj Hospital (TH)
- Mahidol University (TH)
- Bumrungrad International Hospital (TH)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1159/000542926
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Mahidol University
- National Research Council of Thailand
- Faculty of Medicine Siriraj Hospital, Mahidol University